Answers are grounded in this paper and cite their sources.
Computer-aided drug discovery increasingly depends on virtual-screening workflows that remain reliable under severe class imbalance, chemical redundancy and early-recognition constraints. In this study, we developed a leakage-aware prioritization workflow for two cancer-relevant targets, pyruvate kinase M2 (PKM2) and mitogen-activated protein kinase 1 (MAPK1/ERK2), using the LIT-PCBA benchmark. The workflow combines canonical-SMILES curation, duplicate and label-conflict auditing, scaffold-aware validation, a non-learning nearest-active Tanimoto baseline, imbalance-aware machine-learning models, repeated-seed robustness analysis, isotonic probability calibration, ensemble-disagreement estimation, absorption, distribution, metabolism, excretion and toxicity (ADMET)-aware triage, molecular docking, and residue-level contact analysis. Benchmark enrichment is interpreted alongside calibration, ADMET filtering, docking and residue-contact evidence, rather than as a standalone discovery claim. PKM2 emerged as the clearer machine-learning case, with scaffold-aware tree models improving early recognition beyond the nearest-active similarity baseline and yielding top-ranked candidates supported by calibrated activity scores, ADMET profiles, docking scores, and residue-contact fingerprints. MAPK1 provided a biologically relevant contrast target, where ligand-neighborhood similarity remained competitive and downstream structural triage became more decisive than ligand-based ranking alone. These results support a conservative drug-discovery workflow in which leakage-aware benchmarking, calibration, uncertainty, and molecular-level triage remain visible throughout candidate prioritization.
No takes yet. Share an insight, caveat, or question.
Uçar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: